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ABSTRACT

Title:

Anesthesia for the Patient with Mast Cell Activation Disease

Background:

Mast cell activation disease involves the accentuated increase of mast cell
activation and release of chemical mediators, occurring unpredictably to a
variety of triggering stimuli making perioperative management difficult as
both anesthesia and surgery are responsible for triggers of rapid activation
of mast cells in patients with mastocytosis.

Purpose:

To review the challenging presentation, treatment, knowledge, and
anesthetic considerations for patients with mast cell activation disease and
to have an updated source of research of the recent advancements for
success during the perioperative period.

Process:

Research was conducted to extend our understanding of the disease and
how to predict the association between the immediate drug
hypersensitivity and mast cell degranulation. Reports were investigated for
anesthetic medication used for patient with mastocytosis undergoing
procedures requiring anesthesia, the medication side effects reported, and
suggested prophylaxis techniques.

Results:

Preoperative prophylaxis regimes as well as pretreatment for conditions of
intraoperative stress (anesthesia and surgery) need to be conducted to
prevent possible cardiovascular collapse with adult mastocytosis.
Immediate reaction occurring in patients with mastocytosis should be
highly investigated for future documentation of the mechanism of the
reaction.

Implications:

There are currently no official guidelines for intraoperative management
of mast cell activation disease and no known studies have been found to
predict mast cell degranulation in this patient population. Extended
research is needed for perioperative antidotes for the anaphylaxis-like
incidences in mastocytosis patients.

Keywords:

Mast cell activation disease; Systemic mastocytosis; Mast cell activation
syndrome; drug hypersensitivity; anaphylaxis; C-KIT mutation.
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Background

Mast cell activation disease (MCAD) is a condition involving hematopoietic tissue called
mast cells, and the enhanced release of mast cell mediators. Mast cells are found in all human
tissues and secrete over 200 known mediators including histamine, tryptase, chemokines, and
cytokines, playing an important role in our innate and adaptive immunity (Molderings et al.,
2016). Mediators are secreted by mast cells through multiple intercellular pathways in response
to allergic, microbial, and nonimmune triggers in the environment, all which play a role in the
body’s defense mechanisms, growth, and healing (Afrin & Khoruts, 2015).
The term mast cell activation disease is caused by altered mutated genes and
encompasses three similar classes: systemic mastocytosis (SM), idiopathic systemic mast cell
activation syndrome, and mast cell leukemia (Molderings, 2015). This complex disease can also
impersonate other conditions such as “anaphylaxis, leukemia, basophil activation, and other
cardiac conditions leading to profound hypotension” (Klein & Misseldine, 2013, p 589).
In patients without the disease, mast cells usually serve to detect and act upon
“environmental changes and bodily insults and respond by releasing large and variable
assortments of molecular mediators which directly and indirectly influence behavior in other
local and distant cells and tissues, to respond to changes and insults so as to maintain, or restore,
homeostasis” (Afrin & Molderings, 2014, p 2).
History
Mast cells were first discovered in the late 19th century and classification systems and
diagnostic criteria for mastocytosis were first proposed in the 1980s (Afrin & Molderings, 2014).
It was not until the 20th century that the rare systemic mast cell disease was discovered, and just a
quarter century ago when the transmembrane tyrosine kinase receptor (KIT), and somatic D816V
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mutation was revealed (Afrin & Molderings, 2014). Mast cells are “myeloid lineage cells that
arise from bone marrow precursors, more specifically from CD34+ and KIT+ hematopoietic
progenitors” (Pardanani, 2012, p 1117). It was first thought that mast cell disease was neoplastic
in nature and that symptoms were due to pure inappropriate mediator release, and it was only
recently that the KIT mutation was most likely responsible for the immunohistochemical changes
that manifest the symptoms of the disease (Afrin & Molderings, 2014). Ultimately, the umbrella
term “mast cell activation disease” was proposed, suggesting there are known several variants to
the disease.
Epidemiology
Mastocytosis is a rare disease and exact prevalence remains unclear although predictions
have been estimated to affect < 200,000 people in the United States (Brockow, 2014). The
disease occurs both in children and adults with equal gender distribution, and can occur at any
age, although most patients have an onset occurring in less than two years of age, or between the
ages of 20 to 50 years of age (Brockow, 2014). There are two main differences of mastocytosis;
with cutaneous mastocytosis primarily occurring in children, while SM primarily occurring in
the adult population. Indolent SM is the most common form occurring in adults and is assumed
present in 90% to 95% of all patients with mastocytosis (Brockow, 2014). The risk factors for
anaphylaxis in patients with mastocytosis involves a higher basal level of serum tryptase and has
been reported to be present in 22% to 49% of patients (Brockow, 2014). SM in adults also
correlates with excess mortality and morbidity occurring within 5 years after diagnosis is
confirmed, and “inferior survival is associated with advanced age, history of weight loss, anemia,
thrombocytopenia, hypoalbuminemia, and excess bone marrow blasts” (Pardanani, 2012, p
1122).
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Case Report

A 40-year-old woman was scheduled for a hysterectomy, dilation and curettage, with an
intrauterine device insertion for abnormal uterine bleeding. Preoperative vital signs included
blood pressure of 134/79, heart rate of 89, respiratory rate of 16, pulse oxygen saturation of 98
percent, and a temperature of 36.9 degrees Celsius. The patient had a known history of mast cell
activation syndrome, as well as multiple past allergic shock states, hypertension, obstructive
sleep apnea, morbid obesity, anxiety, hypermenorrhea, and left ovarian cyst. The patient was 5'4
and 112 kilograms, with no known allergies. Her home medications included EpiPen
(epinephrine injection USP), Zyrtec (cetirizine), Allegra (fexofenadine), Singular (montelukast),
Zantac (ranitidine, Hcl), Requip (ropinirole Hcl), and labetalol.
The patient was medicated with 2mg midazolam, 25mg diphenhydramine, 10mg
dexamethasone, and 40mg of 1% lidocaine. Induction medications included 150mcg
fentanyl, 14mg etomidate, and 30mg rocuronium. A dexmedetomidine infusion was also initiated
at 0.5mcg/kilogram/hour. With the patient’s history, epinephrine was diluted down into a
10mcg/ml syringe to have on standby. Following intubation, lungs sounds were diminished,
ventilatory tidal volumes were decreased, and oxygen saturations were 70% on 100% FiO2. A
bronchospasm was diagnosed based on rapid increase in peak inspiratory pressure with an
increased height and a “shark-fin” appearance on the capnography waveform, as well as
diminished breath sounds with wheezing. Positive pressure was immediately administered,
sevoflurane gas was increased to 8%, FiO2 was increased to 100%, and 10 puffs of Albuterol
was administered via the endotracheal tube. The patient’s low oxygen saturations and diminished
tidal volumes resolved within 2 minutes and vital signs normalized. At this time, the decision
was made to keep the patient on a deepened anesthetic with sevoflurane at 2.8% in addition to
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the administration of 125mg of solumedrol for anti-inflammatory properties.
For the next 45 minutes, surgery and anesthesia remained uneventful until peak
inspiratory pressures increased and oxygen saturations started to decrease. Once again, a
bronchospasm was observed with the same manifestations as previously. There were no obvious
causes of stress besides current surgical stimulation. Treatment remained the same as before and
symptoms spontaneously resolved within 1 minute. Preparing for the end of the case began with
the decision to extubate deep with sevoflurane at 1.5 MAC with the dexmedetomidine infusion
continuing. The patient neuromuscular blockade was antagonized with 0.6mg of glycopyrrolate
and 4mg of neostigmine, and albuterol was given endotracheally for prophylaxis. After adequate
reversal was confirmed with train of four monitoring, and spontaneous breathing was evaluated
and confirmed with adequate tidal volumes and regular rate, an oral airway was placed, and the
patient was then extubated deep with no signs of bronchospasm. The post anesthesia care unit
(PACU) was called and notified of highly irritable airway, and respiratory therapy was referred
for the patient to be placed on CPAP therapy upon arrival. With 10L oxygen via simple mask,
the patient was delivered safely to the PACU and no bronchospasm occurred during recovery.
Discussion
Diagnosis of MCAD
The World Health Organization (WHO) has a diagnostic classification consensus
criterion for diagnosing MCAD. According to the WHO (2008) guidelines for the diagnosis of
mastocytosis, “Major criterion involve multifocal, dense aggregates of mast cells (15 or more) in
sections of bone marrow or other extracutaneous tissues and confirmed by tryptase
immunohistochemistry or other special stains” (Afrin & Molderings, 2014, p 4). Tryptase
“identifies virtually all cells regardless of maturation or activation stage, or tissue of localization;
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however, neither tryptase nor CD117 immunostaining are able to distinguish between normal
and neoplastic mast cells” (Pardanani, 2012, p 1118). Minor criteria include “atypical or spindled
appearance of at least 25% of the mast cells in the diagnostic biopsy, expression of CD2 and/or
CD25 by mast cells in marrow, blood, or extracutaneous organs, KIT codon 816 mutation in
marrow, blood, or extracutaneous organs, and persistent elevation of serum total tryptase
>20ng/ml” (Afrin & Molderings, 2014, p 4). Diagnosis of MCAD is confirmed with one major
criterion and one minor criterion together, or any three minor criteria. Tryptase is a mast cell
enzyme protease that acts as a “surrogate for mast cell activation, with a test specificity of 98%
and a sensitivity of approximately 83% to 93% for diagnosing SM at tryptase levels greater 20
ng/mL” (Bains & Hsieh, 2010, p 5).
Presentation of MCAD
MCAD has more than 200 mast cell mediators and the clinical presentation involves a
wide array of findings and varies greatly among individuals. According to Afrin, Spruill,
Schabel, & Young-Pierce (2014), potential constitutional manifestations include fatigue, sweats,
flushing, pallor, pruritus, poor healing, and chemical/physical sensitives. Ophthalmologically,
the eyes may become irritated easily and blepharospasm may occur, while otologic symptoms
involve tinnitus, hearing loss, and epistaxis. Adenopathy, adenitis, and splenitis are common
symptoms involving the lymphatic system (Afrin, Spruill, Schabel, & Young-Pierce, 2014).
Common gastrointestinal disturbances include organ inflammation, dyspepsia, reflux,
nausea and vomiting, angioedema, malabsorption, and ascites, while genitourinary symptoms
may include chronic kidney disease, endometriosis, infertility, and miscarriage (Afrin, Spruill,
Schabel, & Young-Pierce, 2014). Neurological and psychiatric manifestations in patients with
MCAD may include headache, sensory/motor neuropathies, seizure disorders, mood
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disturbances, anxiety, and sleep disruption (Afrin, Spruill, Schabel, & Young-Pierce, 2014).
Abnormal electrolytes, impaired glucose control, dyslipidemia, and delayed puberty are
endocrinologic and metabolic possible disturbances (Afrin, Spruill, Schabel, & Young-Pierce,
2014).
Hematologically, there is usually no histologic evidence of mast cell abnormalities in the
bone marrow, although anemia, bleeding disorders, thromboembolic disease, and easy
bruising/bleeding can occur (Afrin, Spruill, Schabel, & Young-Pierce, 2014). Patients with
MCAD have immunologic compromise leading to the hypersensitivity reactions that can be
detrimental in the disease process including the increased risk of malignancy and autoimmunity,
as well as increased infection risk and decreased immunoglobulins (Afrin, Spruill, Schabel, &
Young-Pierce, 2014).
The respiratory system, if irritated, may cause airway inflammation, cough, dyspnea,
wheezing, obstructive sleep apnea, and pulmonary hypertension (Afrin, Spruill, Schabel, &
Young-Pierce, 2014). Lastly, cardiovascular symptoms may include syncope, hypertension or
hypotension, palpitations, edema, chest pain, atherosclerosis, and vascular anomalies (Afrin,
Spruill, Schabel, & Young-Pierce, 2014). Aggressive disease involves “hepatomegaly with
ascites or portal hypertension, splenomegaly with hypersplenism, gastrointestinal malabsorption
with hypoalbuminemia and weight loss, and osteoporosis with pathologic fractures, lytic bone
lesions, and cytopenia” (Bains and Hsieh, 2010, p 6).
Mast Cell Pathogenesis
Mast cells are formed in the bone marrow first as pluripotent stem cells, where they
differentiate and mature into the adult form with the help of stem cell factor (Valent et al., 2003).
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From the bone marrow, mast cell progenitor cells then migrate into the vessels, peripheral
tissues, and nerves where growth and differentiation occur, as well as where the binding of
surface tyrosine kinase occurs (Klein & Misseldine, 2013). Differentiation is not complete until
mast cells reach peripheral tissues, involving most solid tissues including the lung, heart, and
central nervous system (Klein & Misseldine, 2013).
Mast cells have secretary granules that contain proteases, which are the major proteins
that comprise them, with the major protease being tryptase (Carter, Metcalfe, & Komarow,
2014). Surface tyrosine kinase is a “c-kit proto-oncogene product that is expressed on the surface
of pre-committed myelopoietic progenitor cells, mast cell-committed progenitor cells, as well as
mature mast cells” (Valent et al., 2003, p 695). The total tryptase is “comprised of mature
tryptase stored in granules and released only upon activation, and immature (pro) tryptase, which
is constitutively secreted by the mast cell” (Carter, Metcalfe, & Komarow, 2014, p 183).
Surface tyrosine kinase receptors, known as mast cell markers, include CD34, CD13,
CD117 (C-KIT), and CD25 markers to which point mutations can exits at the “C-KIT locus
(Asp816Val, or codon 816) codes for an abnormal cell membrane receptor protein for stem cell
factor, producing clonal mast cell lines that lack normal growth and differentiation” (Klein &
Misseldine, 2013, p 589). It is the surface KIT expression that is exhibited at high levels of
maturation, and the “interaction between the KIT and stem cell factor has been shown to promote
the proliferation, maturation, adhesion, chemotaxis, and survival of mast cells” (Pardanani, 2012,
p. 1119). These mutations are able to be detected in the bone marrow where the C-KIT mutation
can be found in 90% of adults with SM (Klein & Misseldine, 2013). The mutated mast cells have
granules that store and generate a number of vasoactive mediators (histamine, tumor necrosis
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factor-α (TNFα), vascular endothelial growth factor (VEGF), leukotrienes, prostaglandin D2, and
other biologically active molecules (interleukins, proteases, heparin) (Valent et al., 2003).
Treatment
Treatment for SM involves ongoing monitoring, suppression of symptoms, and avoidance
to the triggers of extreme mast cell mediator release. Mediators that cause the origin of
symptoms include “histamine, proteoglycans (heparin), tryptase, acid hydrolases, leukotrienes,
prostaglandins, platelet activating factor, interleukins and tumor necrosis factor” (Scherber &
Borate, 2018, p 16). The disease is highly variable in presentation and treatment is individualized
to the patient’s disease symptoms. Avoidance of emotional stress, excessive physical trauma,
infections, and medications such as contrast, radioactive dyes, opioids, NSAIDS, and
anticholinergics is suggested (Scherber & Borate, 2018).
Patients with asthma or allergic conditions must always have an epinephrine pen on hand.
For symptom control of pruritus’ and flushing, first line treatment includes the use of H1antagonists (cetirizine 5-10mg/day), along with other treatments including leukotriene
antagonists (Montelukast 10mg/day), NSAIDs (aspirin), Psolaren plus UVA photochemotherapy,
and Omalizumab (150mg SC every 2 weeks) (Scherber & Borate, 2018). First line treatment for
symptoms of abdominal pain, diarrhea, and nausea include the use of H2-agonists (ranitidine
150mg BID), with other treatments including proton pump inhibitors (omeprazole 20mg/day),
Cromolyn (100-200mg QID), and corticosteroids (prednisone 0.5-1mg/kg/day) (Scherber &
Borate, 2018).
Symptoms of headache, cognitive impairments, and depression can be treated with H1and H2-antagonists as well as sodium cromolyn (Scherber & Borate, 2018). With patients who
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experience anaphylactoid reactions, treatment consists of administering intramuscular
epinephrine 0.3mg of 1:1,000, although the patient must be competent in the administration of
the injectable epinephrine pen, followed by seeking medical attention immediately (Bains &
Hsieh, 2010). For recurrent hypotension episodes, first line treatment using epinephrine is
advocated, although other treatment methods include H1- and H2-antangonists, corticosteroids,
and cytoreductive therapy (Scherber & Borate, 2018). Candidates for cytoreductive therapy is
“only indicated in patients with target organ damage due to SM, typically patients with
aggressive systemic mastocytosis, SM with associated clonal hematologic non–mast cell lineage
disease, and mast cell leukemia disease categories” (Bains & Hsieh, 2010, p 6).
Lastly, osteoporosis symptoms may be treated with bisphosphonate and purine
nucleoside analogs (Scherber & Borate, 2018). To current date, Midostaurin, a “tyrosine kinase
inhibitor, has a response rate of 60% in patients with advanced SM which is effective against
KIT- D816V” (Scherber & Borate, 2018, p 18). Pharmacotherapies also used for mastocytosis
therapy include interferon (IFN)-α, “commonly regarded as the first-line cytoreductive therapy in
symptomatic SM and shown to improve skin, gastrointestinal, and systemic symptoms associated
with MC degranulation, as well as an impact on skeletal disease through its ability to improve
bone density” (Pardanani, 2012, p 1123). For all subtypes of SM, 2-chlorodeoxyadenosine, a
cytoreductive agent, is another successful therapy for patients who experience intolerance to
IFN-α (Padrdanini, 2012). Other agents currently being studied for the treatment of SM include
Imatinib, Masitinib, Dasatinib, and Hydroxycarbamide (Scherber & Borate, 2018).
Differential Diagnosis
Systemic mastocytosis and the disease symptoms may have common manifestations of
other cofounding disease processes. Mast cell activation can endocrinologically be similar to the
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effects of a pheochromocytoma, autoimmune vasculitis, carcinoid syndrome, and neurological
fibromyalgia (Scherber & Borate, 2018). Its digestive symptoms may be diagnosed as celiac
disease, irritable bowel disease, as well as simple intolerance to gluten (Scherber & Borate,
2018).
To diagnose mastocytosis, the presence of typical clinical symptoms including vomiting,
malabsorption, abdominal pain, diarrhea, nausea, blisters, myalgia, pruritus, ascites, fevers/chills,
migraines, anorexia, bone pain, and asthma are common (Scherber & Borate, 2018).
Additionally, serum total tryptase must be increased “by at least 20% above baseline, 2ng/ml
during or within 4 hours after a symptomatic period and must have the response of clinical
symptoms to mast cell blocking agents such as cromolyn” (Scherber & Borate, 2018, p 12).
Serum tryptase levels can be elevated in diseases such as “myeloid neoplasms, acute myeloid
leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia, refractory anemia, and
hypereosinophilic syndrome, and thus, elevated tryptase levels are only indicative of SM in the
absence of other hematologic malignant neoplasms” (Bains & Hsieh, 2010, p 5). If the patient’s
history and symptoms are consistent with mastocytosis or the common differential diagnosis’ the
KIT D816V analysis should be evaluated for possible clonality as the cause of their symptoms
(Scherber & Borate, 2018). Systemic mastocytosis is a “disorder of clonal proliferation of mast
cells and the diagnosis is established by detection of mast cells with abnormal morphologic
features and immunophenotypes in the bone marrow or other extracutaneous organs and specific
mutations in its growth factor (c-KIT) receptor” (Bains & Hsieh, 2010, p 4).
Triggers
For people with mast cell disease, anesthesia is a risk for patients undergoing surgical
procedures due to the stress response from surgery as well as the medications needed to induce
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and maintain anesthesia. Mast cell degranulation triggers include heat, friction, opioids,
anesthetics, contrast, vaccines, non-steroidal anti-inflammatory drugs, insect bites, anxiety, and
stress (Scherber & Borate, 2018). Other ‘triggering’ factors include medications (some
antibiotics, amphotericin B, tramadol, and ketorolac), alcohol or radiographic contrast
media (Valent et al., 2003).
Intraoperative drugs noted to take part in mast cell degranulation include aspirin,
thiamine, polymyxin-B, quinine, dextromethorphan, anticholinergic preparations, alphaadrenergic blockers, d-tubocurarine, metocurine, doxacurium, etomidate, enflurane, isoflurane,
and lidocaine (Bains & Hsieh, 2010). Anesthetic drugs that have been known to have
experimental histamine release and mast cell degranulation include alfentanil, cisatricurium,
codeine, fentanyl, ketamine, meperidine, midazolam, morphine, Propofol, rocuronium,
succinylcholine, sufentanil, thiopental, and vecuronium (Klein & Misseldine, 2013).
It is known that some foods, as well as mechanical stress, pressure, physical exertion, and
thermal stress can cause histamine release (Klein & Misseldine, 2013). Examples of stress
inducing effects in the operating room include patient anxiety, cold room temperature, bright
lights, hemodynamic stress of induction medications, direct laryngoscopy, surgical stimulation,
emergence from anesthesia, and extubation. Degranulation signs can be as discrete as a small
rash or flushing, to bronchospasm, profound hypotension, and cardiovascular collapse.
Cardiovascular symptoms include tachycardia, syncope and anaphylaxis, while respiratory
symptoms include irritable lower respiratory tract rhinitis, and lymphadenopathy (Bains &
Hsieh, 2010).
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Preoperative management
Due to perioperative immediate reactions as a result of mast cell degranulation, a
thorough preoperative plan should be in place. Anaphylaxis due to a “massive mast cell mediator
release is present in a significant portion of SM patients (22–49%) and can be elicited by either
known or unknown triggers through diverse mechanisms involving IgE- or non-IgE mediated
pathways” (Matito et al., 2015, p. 48). The severity of reactions that occur in the operating room
depend on the “cardiovascular homeostasis disturbances, as profound vasodilatation following
mast cell degranulation with subsequent histamine release may, at the extreme, result in lifethreatening conditions” (Renauld et al., 2011, p 458).
Suggested prophylaxis regimens found throughout the medical literature suggest that
anti-histamines and steroids be administered, a baseline tryptase level should be acquired, and
identification should be provided to the patient with MCAD with a medical alert bracelet (Klein
& Misseldine, 2013). If diagnosis is suspected, a thorough preoperative “physical examination
and determination of serum tryptase level, complete blood count, and hepatic enzyme levels are
recommended” (Klein & Misseldine, 2013, p 590). Currently there are no guidelines for
preoperative prophylaxis regimes, only case reports found in recent literature.
Preparation for cardiovascular collapse is essential for safety, especially in a known
mastocytosis patient undergoing anesthesia for a surgical case. It is important that the anesthesia
practitioner is aware that patients with mastocytosis “experience both immune (IgE-related) and
non-immune anaphylaxis, and the overall incidence of anaphylaxis in patients with mastocytosis
has been reported to be higher than in the general population” (Klein & Misseldine, 2013, p
591). The most substantial mediator is histamine. The prophylactic use of H1-receptor and H2receptor antagonists are given to prevent preformed histamine release. Histamine is known to act
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on four different histamine receptors, which all cause capillary membrane permeability, urticaria,
swelling hypotension and vasodilation, gastrointestinal and bronchial smooth muscle contraction,
mucous and edema formation, pruritus, and gastric acid production (Carter, Metcalfe, &
Kamarow, 2013). H1 receptors “modulate bronchial and GI smooth muscle contraction and may
be blocked by antihistamines such as diphenhydramine (Benadryl) and cetirizine (Zyrtec), while
stimulation of gastric acid secretion by parietal cells is regulated by H2 receptors and is inhibited
by H2 antagonists like ranitidine (Zantac)” (Carter, Metcalfe, & Kamarow, 2013, p 183).
Glucocorticoids are used as mast cell stabilizers and have anti-inflammatory properties for the
preoperative patient with mastocytosis (Klein & Misseldine, 2013).
Measuring a baseline tryptase level preoperatively is also recommended to evaluate the
degree of elevation. As discussed previously, “mast cell degranulation occurs secondary to a
variety of non-immune triggers specific for each patient, including psychological, traumatic
(tourniquet), and physical (rubbing, extreme temperatures) agents”, suggesting that surgery itself
can lead to mast cell triggered mediator release (Renauld et al., 2011).
Intraoperative Management
Continue to maintain the avoidance of triggers that will cause mast cell mediator release.
There are documented anesthetic drugs that are considered initiators of mast cell degranulation
and activation in patients with mastocytosis. As discussed previously, anesthetic drugs that have
been known to have experimental histamine release and mast cell degranulation include
alfentanil, cisatricurium, codeine, fentanyl, ketamine, meperidine, midazolam, morphine,
Propofol, rocuronium, succinylcholine, sufentanil, thiopental, and vecuronium (Klein &
Misseldine, 2013). Other intraoperative drugs noted to take part in mast cell degranulation
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include aspirin, thiamine, polymyxin-B, quinine, dextromethorphan, anticholinergic
preparations, vancomycin, alpha-adrenergic blockers, d-tubocurarine, metocurine, doxacurium,
etomidate, enflurane, isoflurane, and lidocaine (Bains & Hsieh, 2010).
Matito et al., (2014) reviewed 501 mastocytosis patients who underwent anesthetic
techniques including general, regional, and local anesthetic techniques, and found that, in adult
mastocytosis patients who “underwent anesthetic procedures, the frequency of anaphylaxis was
0.6% and mast cell mediator release symptoms was 7% respectively and despite this, anesthetic
procedures are considered high-risk in SM patients since severe reactions (e.g. systemic
hypotension/anaphylactic reactions and coagulopathy) can result in death in individual patients
that have been recurrently reported” (Matito et al., 2015, p 53).
Histamine is largely responsible for most mastocyte degranulation and will respond to
H1- and H2-histamine receptor antagonists. Although mast cell degranulation is unpredictable
with occurrence, other “‘antimediator’ drugs that are beneficial include glucocorticoids,
cromolyn sodium, acetylsalicylic acid (aspirin) and leukotriene antagonists” (Valent et al., 2003,
p 705). Although aspirin is often contraindicated in patients with mast cell disease due to its
ability to cause mast cell degranulation, it is a cyclo-oxygenase inhibitor, which can help if the
culprit of degranulation is prostaglandin D2. Gadolinium, an intravenous contrast agent, has
typically been considered safe in patients with mast cell degranulation, although if radiocontrast
medium needs to be administered, “all patients should be premedicated with steroids and
antihistamines before receiving iso-osmolar radiocontrast media” (Bains & Hseih, 2010, p 6).
Intraoperative Crisis Management
Aggressive treatment is needed during a mast cell degranulation crisis and epinephrine
should always available and ready for use. In patients with mastocytosis, prompt administration
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of epinephrine is indicated for treatment of severe spontaneous hypotensive episodes. Treatment
is aimed at opposing the effects of mediators in the body that have been released while in turn,
stabilizing the mast cell membrane (Vaughan & Jones, 2002). There has been known episodes
of unpredictable profound hypotension in patients with SM, and most reasonably caused by mast
cell mediators histamine and prostaglandin D2 (Vaughan & Jones, 2002). Any reaction, from
isolated flushing to anaphylaxis should be investigated in order to identify the mechanism of the
reaction and performing an IgE specific assay is recommended to rule out if the reaction was
from the disease process or drug/agent-induced IgE-mediated mechanism (Klein & Misseldine,
2013). Epinephrine has been known to have added benefit not only for cardiovascular symptoms,
but the beta-2 adrenoceptors can be used to prevent degranulation on the mast cell (Vaughan &
Jones, 2002). In patients with SM, bronchospasm is said to usually not occur, although due to
where mast cells populate and their exposure to the external environment (skin, gastrointestinal,
and respiratory tracts), risks are present for severe mast cell degranulation (Renauld et al., 2011).
Postoperative Management
Continuing treatment including antihistamines, leukotriene antagonists, and steroids has
not been found as an added benefit in the postoperative period, as it does in the preoperative
period, however extended post anesthesia management and monitoring is still recommended in
patients with mastocytosis (Klein & Misseldine, 2013). It is also highly suggested that an
“immediate reaction occurring in patients with mastocytosis should be investigated extensively,
including measurement of serum tryptase levels and skin tests, in order to document the
mechanism of the reaction, either histamine release due to the disease itself or due to concurrent
drug/agent-induced IgE-mediated mechanism” (Renauld et al., 2011, p 456).
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Conclusion

The effect that anesthesia and surgery have on potential mast cell mediator release in
patients with mastocytosis is poorly investigated. With perioperative anaphylaxis incidences
being much higher in patients with mastocytosis, anesthesia practitioners need evidence-based
research guidelines to avoid and control mast cell mediator-associated symptoms. Currently,
there is limited data and no official guidelines for intraoperative management of mast cell
activation disease. Extended research is needed to assist in predicting and treating the
anaphylaxis-like incidences that can occur with this disease.
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